Pharmacogenomic test that predicts response to inhaled corticosteroids in adults with asthma likely to be cost-saving

Pharmacogenomics

Volumn 16, Issue 6, 2015, Pages 591-600

  Wu, Ann Chen ^a,b   Gay, Charlene ^b   Rett, Melisa D ^a   Stout, Natasha ^a   Weiss, Scott T ^c   Fuhlbrigge, Anne L ^c  

^a HARVARD PILGRIM HEALTH CARE INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

asthma; cost effectiveness; inhaled corticosteroids; pharmacogenomics; predictive test

Indexed keywords

CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; ASTHMA; COMPUTER MODEL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PHARMACOGENOMICS; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY AND SPECIFICITY; COST BENEFIT ANALYSIS; ECONOMICS; FORECASTING; INHALATIONAL DRUG ADMINISTRATION; PHARMACOGENETICS; PROCEDURES; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ASTHMA; COST SAVINGS; COST-BENEFIT ANALYSIS; FORECASTING; HUMANS; PHARMACOGENETICS; TREATMENT OUTCOME;

EID: 84929456263     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.15.28     Document Type: Article

References (44)

1. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, Lahive K, Leboff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. N. Engl. J. Med. 345(13), 941-947 (2001).
2. Isaksson M. Skin reactions to inhaled corticosteroids. Drug Saf. 24(5), 369-373 (2001).
3. Jick SS, Vasilakis-Scaramozza C, Maier WC. The risk of cataract among users of inhaled steroids. Epidemiology 12(2), 229-234 (2001).
4. Robinson DS, Campbell DA, Durham SR, Pfeffer J, Barnes PJ, Chung KF. Systematic assessment of difficult-to-treat asthma. Eur. Respir. J. 22(3), 478-483 (2003).
5. Strunk RC, Sternberg AL, Bacharier LB, Szefler SJ. Nocturnal awakening caused by asthma in children with mild-to-moderate asthma in the childhood asthma management program. J. Allergy Clin. Immunol. 110(3), 395-403 (2002).
6. Chan MT, Leung DY, Szefler SJ, Spahn JD. Difficult-to-control asthma: clinical characteristics of steroid-insensitive asthma. J. Allergy Clin. Immunol. 101(5), 594-601 (1998).
7. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br. Med. Bull. 56(4), 1054-1070 (2000).
8. Szefler SJ, Martin RJ, King TS et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J. Allergy Clin. Immunol. 109(3), 410-418 (2002).
9. Sharek PJ, Bergman DA. The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis. Pediatrics 106(1), E8 (2000).
10. Patel L, Wales JK, Kibirige MS, Massarano AA, Couriel JM, Clayton PE. Symptomatic adrenal insufficiency during inhaled corticosteroid treatment. Arch. Dis. Child. 85(4), 330-334 (2001).
11. Wu AC, Himes BE, Lasky-Su J et al. Development of a pharmacogenetic predictive test in asthma: proof of concept. Pharmacogenet. Genomics 20(2), 86-93 (2010).
12. Xu M, Tantisira KG, Wu A et al. Genome wide association study to predict severe asthma exacerbations in children using random forests classifiers. BMC Med. Genet. 12, 90 (2011).
13. McGeachie MJ, Wu AC, Chang HH, Lima JJ, Peters SP, Tantisira KG. Predicting inhaled corticosteroid response in asthma with two associated SNPs. Pharmacogenomics J. 13(4), 306-311 (2013).
14. Wu AC, Himes BE, Tantisira K, Weiss ST. Development of a pharmacogenetic test that predicts response to inhaled corticosteroids in asthma patients [Abstract 304]. Presented at: 59th Annual Meeting of The American Society of Human Genetics. Honolulu, Hawaii, 20-24 October 2009.
15. Phillips KA, Veenstra DL, Ramsey SD, Van Bebber SL, Sakowski J. Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. Am. J. Manag. Care 10(7 Pt 1), 425-432 (2004).
16. Cost-Effectiveness in Health and Medicine. Gold MR, Siegel JE, Russell LB, Weinstein MC (Eds). Oxford University Press, New York, USA (1996).
17. Fuhlbrigge AL, Bae SJ, Weiss ST, Kuntz KM, Paltiel AD. Cost-effectiveness of inhaled steroids in asthma: impact of effect on bone mineral density. J. Allergy Clin. Immunol. 117(2), 359-366 (2006).
18. Paltiel AD, Fuhlbrigge AL, Kitch BT et al. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model. J. Allergy Clin. Immunol. 108(1), 39-46 (2001).
19. Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J. Allergy Clin. Immunol. 120(5), 1146-1152 (2007).
20. Expert Panel Report 3 (EPR-3). Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J. Allergy Clin. Immunol. 120(5 Suppl.), S94-S138 (2007).
21. Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. Eur. Respir. J. 24(5), 822-833 (2004).
22. Meltzer EO, Lockey RF, Friedman BF et al. Efficacy and safety of low-dose fluticasone propionate compared with montelukast for maintenance treatment of persistent asthma. Mayo Clin. Proc. 77(5), 437-445 (2002).
23. Pearlman DS, White MV, Lieberman AK et al. Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. Ann. Allergy Asthma Immunol. 88(2), 227-235 (2002).
24. Bleecker ER, Welch MJ, Weinstein SF et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J. Allergy Clin. Immunol. 105(6 Pt 1), 1123-1129 (2000).
25. Busse W, Wolfe J, Storms W et al. Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial. J. Fam. Pract. 50(7), 595-602 (2001).
26. Nathan RA, Minkwitz MC, Bonuccelli CM. Two first-line therapies in the treatment of mild asthma: use of peak flow variability as a predictor of effectiveness. Ann. Allergy Asthma Immunol. 82(5), 497-503 (1999).
27. Kim KT, Ginchansky EJ, Friedman BF et al. Fluticasone propionate versus zafirlukast: effect in patients previously receiving inhaled corticosteroid therapy. Ann. Allergy Asthma Immunol. 85(5), 398-406 (2000).
28. Williams B, Noonan G, Reiss TF et al. Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older. Clin. Exp. Allergy 31(6), 845-854 (2001).
29. Krishnan JA, Bender BG, Wamboldt FS et al. Adherence to inhaled corticosteroids: an ancillary study of the Childhood Asthma Management Program clinical trial. J. Allergy Clin. Immunol. 129(1), 112-118 (2012).
30. Mallal S, Phillips E, Carosi G et al. HLA-B∗5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008).
31. Drug Topics Red Book. Medical Economics Company, Montvale, NJ, USA (2009).
32. Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur. Respir. J. 12(6), 1322-1326 (1998).
33. Cisternas MG, Blanc PD, Yen IH et al. A comprehensive study of the direct and indirect costs of adult asthma. J. Allergy Clin. Immunol. 111(6), 1212-1218 (2003).
34. Stanford R, Mclaughlin T, Okamoto LJ. The cost of asthma in the emergency department and hospital. Am. J. Respir. Crit. Care Med. 160(1), 211-215 (1999).
35. Lewis CE, Rachelefsky G, Lewis MA, De La Sota A, Kaplan M. A randomized trial of A.C.T. (asthma care training) for kids. Pediatrics 74(4), 478-486 (1984).
36. Ross RN, Morris M, Sakowitz SR, Berman BA. Cost-effectiveness of including cromolyn sodium in the treatment program for asthma: a retrospective, record-based study. Clin. Ther. 10(2), 188-203 (1988).
37. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N. Engl. J. Med. 326(13), 862-866 (1992).
38. Coventry JA, Weston MS, Collins PM. Emergency room encounters of pediatric patients with asthma: cost comparisons with other treatment settings. J. Ambul. Care Manage. 19(2), 9-21 (1996).
39. Segal R, Ried LD, Mackowiak J. Cost of asthma illnesses: emergency department visits without admission. Pharm. Pract. Manag. Q. 15(3), 72-82 (1995).
40. Moy ML, Fuhlbrigge AL, Blumenschein K et al. Association between preference-based health-related quality of life and asthma severity. Ann. Allergy Asthma Immunol. 92(3), 329-334 (2004).
41. Wu AC, Li L, Fung V et al. Use of leukotriene receptor antagonists are associated with a similar risk of asthma exacerbations as inhaled corticosteroids. J. Allergy Clin. Immunol. Pract. 2(5), 607-613 (2014).
42. O'Brien BJ, Gertsen K, Willan AR, Faulkner LA. Is there a kink in consumers' threshold value for cost-effectiveness in health care? Health Econ. 11(2), 175-180 (2002).
43. Dowie J. Why cost-effectiveness should trump (clinical) effectiveness: the ethical economics of the South West quadrant. Health Econ. 13(5), 453-459 (2004).
44. Rand C, Bilderback A, Schiller K, Edelman JM, Hustad CM, Zeiger RS. Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial. J. Allergy Clin. Immunol. 119(4), 916-923 (2007).